Compare NMIH & ADPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | NMIH | ADPT |
|---|---|---|
| Founded | 2011 | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Property-Casualty Insurers | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.8B | 2.7B |
| IPO Year | 2013 | 2019 |
| Metric | NMIH | ADPT |
|---|---|---|
| Price | $43.05 | $22.54 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 9 |
| Target Price | ★ $43.25 | $17.78 |
| AVG Volume (30 Days) | 469.0K | ★ 2.7M |
| Earning Date | 04-30-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 11.06 | ★ 63.89 |
| EPS | ★ 1.28 | N/A |
| Revenue | ★ $706,440,000.00 | $276,976,000.00 |
| Revenue This Year | N/A | $3.98 |
| Revenue Next Year | $4.34 | $22.72 |
| P/E Ratio | $33.40 | ★ N/A |
| Revenue Growth | 8.52 | ★ 54.77 |
| 52 Week Low | $34.84 | $9.96 |
| 52 Week High | $43.36 | $23.15 |
| Indicator | NMIH | ADPT |
|---|---|---|
| Relative Strength Index (RSI) | 67.48 | 61.02 |
| Support Level | $36.61 | $15.08 |
| Resistance Level | $43.36 | $22.97 |
| Average True Range (ATR) | 0.92 | 1.26 |
| MACD | -0.02 | -0.14 |
| Stochastic Oscillator | 92.89 | 80.17 |
NMI Holdings Inc through its subsidiaries provides private mortgage guaranty insurance. The company offers mortgage insurance, reinsurance on loans, and outsourced loan review services to mortgage loan originators. It serves national and regional mortgage banks, money center banks, credit unions, community banks, builder-owned mortgage lenders, Internet-sourced lenders, and other non-bank lenders. It protects lenders and investors from default-related losses on a portion of the unpaid principal balance of a covered mortgage.
Adaptive Biotechnologies Corp is a company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is a test authorized by the FDA for the detection and monitoring of minimal residual disease (MRD) in patients with multiple myeloma (MM), B cell acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL) and is also available as a CLIA-validated laboratory developed test (LDT) for patients with other lymphoid cancers. The company has two operating segments: Minimal Residual Disease and Immune Medicine. The company generates the majority of its revenue from the Minimal Residual Disease segment.